Table 2 |
|||||
|
Risk of AD with and without prior use of NSAIDs, stratified by APOE-ε4 carrier status |
|||||
|
EXPOSURE |
AD (N = 691) |
NON-DEMENTED FAMILY MEMBERS (N = 973) |
CRUDE ODDS RATIO (95% CI) |
AGE-ADJUSTED ODDS RATIO (95% CI) |
ADJUSTED ODDS RATIO (95% CI) |
|
|
|||||
|
Overall |
|||||
|
No NSAIDs |
667 |
907 |
1.0 |
1.0 |
1.0 |
|
Use of NSAIDs |
24 |
66 |
0.49 (0.31, 0.80) |
0.55 (0.34, 0.88) |
0.64 (0.38, 1.05)* |
|
Having no ε4 alleles |
|||||
|
No NSAIDs |
231 |
556 |
1.0 |
1.0 |
1.0 |
|
Use of NSAIDs |
12 |
47 |
0.61 (0.32, 1.18) |
0.75 (0.38, 1.46) |
0.78 (0.39, 1.52)** |
|
Having at least one ε4 allele |
|||||
|
No NSAIDs |
436 |
351 |
1.0 |
1.0 |
1.0 |
|
Use of NSAIDs |
12 |
19 |
0.51 (0.24, 1.06) |
0.47 (0.24, 0.96) |
0.49 (0.24, 0.98)** |
|
|
|||||
|
*Adjusted for age, sex, ethnicity, education, and APOE-ε4 status. **Adjusted for age, sex, ethnicity, and education. ***NSAID*APOE-ε4 interaction p-value = 0.04. |
|||||
|
Yip et al. BMC Geriatrics 2005 5:2 doi:10.1186/1471-2318-5-2 |
|||||
